Are Shares Criminally Undervalued At GlaxoSmithKline Plc, Aberdeen Asset Management Plc & International Consolidated Airlines Group SA?

Are there bargains to be found at GlaxoSmithKline Plc (LON: GSK), Aberdeen Asset Management Plc (LON: ADN) and International Consolidated Airlines Group SA (LON: IAG)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Low valuations combined with dividends have always been the value-hunter’s greatest dream. With price/earnings ratios below 11 and regular dividends, is the market undervaluing GlaxoSmithKline (LSE: GSK), Aberdeen Asset Management (LSE: ADN) and International Consolidated Airlines Group (LSE: IAG)?

Dividend cut ahead?

Emerging markets-focused asset manager Aberdeen has suffered 11 straight quarters of withdrawals due to poorly performing funds and the meltdown in developing economies. Plummeting share prices mean the company now offers an 8% yield and a P/E ratio of 11. While investors may find these numbers hard to resist, there could be worse to come for shares.

Earnings are expected to collapse by more than a third this year, which will barely cover dividend payouts. If major institutional clients continue fleeing Aberdeen’s funds, a dividend cut becomes very likely. And with any turnaround in market sentiment towards developing economies out of sight, I’m happy to sit on the sidelines and wait for a turnaround before plonking my money into shares.

Should you invest £1,000 in Investec Group Limited right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Investec Group Limited made the list?

See the 6 stocks

Safe play

Pharmaceuticals giant GSK certainly appears to fit the bill of a bargain share, trading at a P/E of eight and offering a 5.8% yielding dividend. Unfortunately, this eye-catching valuation is due to one-off profits received from an asset swap deal with Novartis. GSK’s 2016 forecast P/E is a more reasonable 16 times earnings.

Despite this higher valuation, GSK could still be an attractive opportunity for investors. Management has shifted focus from being a pureplay drugs manufacturer to having a more diversified portfolio of drugs, consumer healthcare goods, and vaccines. The healthcare segment and vaccines now account for 26% and 16% of revenue, respectively, providing less lumpy revenue streams year-after-year.

The traditional pharmaceuticals division will still be there to provide growth for GSK, with the most promising option being a series of new HIV treatments. HIV treatments already contribute 29% of profits, and this number is expected to continue growing as GSK gains market share. Earnings are expected to grow 12% next year, and increase from there. A once-again-safely-covered dividend and growth potential make me think that GSK could be a relatively safe play for income-hungry investors going forward.

Proving us all wrong

The parent of British Airways and Iberia, IAG, has been proving wrong the long-held sentiment that airline shares were good for little more than losing your money. Share prices are up 145% over the past five years and yet the shares trade at a mere 6.7 times forward earnings. This low valuation and a 3.5% dividend pencilled-in for 2016 will surely have value investors eagerly adding the shares to their watch lists.

While plummeting oil prices have played their part, increased efficiency at both BA and Iberia have been the largest drivers of growth. In fact, fuel prices for the company fell only 6.3% last year while profits rose a full 51%. If the company were only doing well thanks to historically low oil prices, I would be wary of the shares. However, with the company expanding astutely only on high-margin routes and buying up stakes in turnaround carriers such as Aer Lingus, IAG does have the potential to break the mould and be an airline that actually provides high shareholder returns.

Should you invest £1,000 in Investec Group Limited right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Investec Group Limited made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ian Pierce has no position in any shares mentioned. The Motley Fool UK has recommended Aberdeen Asset Management and GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

At $184, I reckon this S&P 500 juggernaut is still on sale

Our writer sees Amazon (NASDAQ:AMZN) as an attractive S&P 500 stock to consider while it is priced 23% lower than…

Read more »

Investing Articles

Cheap FTSE 250 shares to consider buying right now?

These FTSE 250 growth stocks had weak starts to 2025, and face short-term uncertainty. But their long-term valuations could be…

Read more »

Investing Articles

As stocks dive, is this a rare chance for ISA investors to build generational wealth?

Globally, stocks have pulled back significantly following the announcement of tariffs by the US president. Is this an opportunity for…

Read more »

Investing Articles

2 ultra-cheap shares to consider right now!

These cheap UK shares offer considerable growth and income potential over the long term, reckons our writer Royston Wild.

Read more »

Investing Articles

Legal & General Group shares go ex-dividend on 24 April – time to grab that 9% yield?

Harvey Jones holds Legal & General Group shares and is already looking forward to the next bumper dividend from this…

Read more »

Young female analyst working at her desk in the office
Investing Articles

3 FTSE 100 dividend stocks to consider buying while they’re on sale

Paul Summers reckons canny investors should think about snapping up quality, dividend-paying stocks while they're going cheap

Read more »

Investing Articles

2 cheap passive income shares to consider buying right now

The passive income we can earn from the UK stock market looks set to climb this year, and could even…

Read more »

Investing Articles

Down 15% in a month, this FTSE 100 dividend share offers investors a stunning 10.8% yield

Harvey Jones plucks out a FTSE 100 dividend share that offers frankly a quite staggering yield and is now a…

Read more »